The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Dr. Michael J. Galvin, In the Matter of
20260835: Kainos Capital Partners III LP; Heartwood Partners III, L.P.
20260846: SCF Holdings I-B (Lux) SCSp; Chicago Parking Meters, LLC
20260862: Janus Henderson Group plc; Richard Bernstein
20260904: Thompson Street Capital Partners VI, L.P.; Jeffery L. Karpel
2024-00074_redacted_il_makiage_oddity_tech_173_results
2023-01656_redaction_il_makiage_oddity_tech
2024-00074_redacted_spoiledchild_30_results
2023-01824_redacted_oddity_sampling
2023-01463_redacted_apple_billing_practice
2021-01042_apple_redacted
2023-00596_apple_redacted
Zvi Kriple, In the Matter of
2024-00705_apple_redacted_
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.